Concepedia

Suramin prevents the development of diabetic kidney disease by inhibiting <scp>NLRP3</scp> inflammasome activation in <scp>KK‐Ay</scp> mice

Kaori Oda, Satoshi Miyamoto, Ryo Kodera, Jun Wada, Kenichi Shikata

Journal of Diabetes Investigation · 2022 · 11 citations · 29 references

DOIFull text

Open access

Abstract

These results suggest that the NLRP3 inflammasome is activated in a diabetic kidney and that inhibition of the NLRP3 inflammasome with suramin protects against the progression of early stage DKD.

References

29

Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and Hospitalization

Alan S. Go, Glenn M. Chertow, Dongjie Fan et al. · New England Journal of Medicine · 2004 · 11.2K citations · Full text

Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64)

Amanda Adler, Richard Stevens, Susan E. Manley et al. · Kidney International · 2003 · 1.8K citations

, , +9

The Burden of Mortality Attributable to Diabetes

Gojka Roglić, Nigel Unwin, Peter H. Bennett et al. · Diabetes Care · 2005 · 818 citations · Full text

Upregulated NLRP3 Inflammasome Activation in Patients With Type 2 Diabetes

Hyemi Lee, Jwa-Jin Kim, Hyun Jin Kim et al. · Diabetes · 2012 · 722 citations · Full text

, , +23

Suramin: a reversible P<sub>2</sub>‐purinoceptor antagonist in the mouse vas deferens

Philip M. Dunn, A G Blakeley · British Journal of Pharmacology · 1988 · 426 citations · Full text